"Drug pricing may vary
significantly based on contracts and utilization. Additionally, patients who
relapse may require additional therapy, which could increase the overall cost
of treatment."
— April Kunze, Pharm.D., senior director of clinical formulary
development and trend management strategy for Prime Therapeutics LLC, talked
with AIS's RADAR on Drug
Benefits about new approaches to treating Hepatitis C, and why
shortening the length of expensive drug treatments might not save money.
No comments:
Post a Comment